-- 摩根士丹利週一發布的一份報告指出，隨著BioMarin Pharmaceutical (BMRN)收購Amicus Therapeutics (FOLD)，該公司正轉型為一家業務範圍更廣的罕見疾病平台。此次收購新增了兩款已核准藥物，並降低了對Voxzogo的依賴。 報告稱，Amicus的收購重塑了BioMarin的前景，新增了Galafold和Pombilityi以及Opfolda，這些產品與公司的全球商業網絡高度契合。摩根士丹利預計，到2030年，這些療法將帶來超過13億美元的收入。 報告也指出，此次收購預計將在完成後立即加速營收成長，並在12個月內提升非GAAP收益，而「顯著提升」將從2027年開始。 BioMarin於週一完成了對Amicus的收購，交易金額為48億美元。 摩根士丹利恢復了對BioMarin股票的評級，給予「增持」評級，目標價為120美元。
Price: $54.08, Change: $+0.90, Percent Change: +1.68%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:AVB reported Q1 2026 results with FFO at $2.83, flat Y/Y but $0.03 above consensus. Rental revenue rose 3.3% Y/Y while operating expenses surged 4.7%, resulting in weak same-store NOI growth of just 0.2% Y/Y. Same-store occupancy was flat at 96.1% vs. 96.0% a year ago, and turnover decreased to 31.6% from 32.1%. We like AVB's portfolio profile, with 80% exposure to premier East Coast (35%) and West Coast (45%) markets. We are monitoring the 20% Sun Belt allocation, which faces new supply pressures. The trust is guiding Q2 2026 FFO of $2.72-$2.82 per share, with full-year 2026 same-store NOI ranging from -0.7% to +1.3%. AVB has $3.39B in community developments underway that target suburban markets. We think total debt of $9.4B is manageable. Utility expenses surged 12.5% Y/Y in New England and Mid-Atlantic markets, reflecting ongoing inflationary pressures. Despite these cost headwinds, we believe there's financial flexibility to fund the development pipeline in high-barrier-to-entry coastal markets.
New Zealand King Salmon Investments (ASX:NZK, NZE:NZK) has advanced its Blue Endeavour pilot project with the successful installation of both pilot pens and a mooring grid, marking a key milestone in its open-ocean salmon farming project, according to a Tuesday filing with the Australian and New Zealand bourses.The project is expected to receive its first fish in late May to early June, delivered by the recently arrived Ronja King wellboat, which will begin operations after completing clearance and onboarding in the coming weeks, the filing added.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BRO posted Q1 2026 adjusted EPS of $1.39 versus $1.29, modestly topping our $1.37 estimate and the $1.36 consensus view, though revenue growth of 35% to $1.9B was acquisition-driven with $435M from deals. Organic revenues were flat Y/Y at $1.35B, lagging our 4% to 8% growth forecast, while Q1 EBIT margins contracted to 28.0% from 30.4% due to acquisition costs and doubled interest expense. We believe the shares lack a near-term catalyst given below-peer organic growth rates and margin compression that removes BRO's historical premium valuation justification. Management characterized business conditions as "challenging," representing a shift from last quarter's "stable" assessment. BRO completed 43 acquisitions in 2025, including the $9.8B Accession deal, and we expect acquisitions to remain central to growth strategy as organic growth slows. In our view, the combination of flat organic growth and margin contraction will pressure the shares' premium valuation to peers.